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INTRODUCTION

Liver  dysfunction  is  frequently  accompanied  by  a  hemostatic 
defect.Bleeding is usually due to an anatomic lesion that is exacerbated by a 
hemostatic  defect.  Most  patients  with  chronic  liver  disease   bleed  from 
complications of portal hypertension,esophageal varices, or gastritis and peptic 
ulcer  disease.Portal  hypertension  also  causes  splenomegaly,  with  splenic 
sequestration  of  platelets  and  thrombocytopenia,  which  contributes  to  the 
hemostatic defect.   Other causes of bleeding are variceal rupture,coagulation 
disorders due to multiple causes : decreased synthesis of  clotting and inhibitor 
factors ; decreased clearance of activated factors , quantitative and qualitative 
platelet  defects  ,  hyperfibrinolysis  and accelerated  intravascular  coagulation. 
Bleeding from  the gastrointestinal tract is also an important determining factor 
of mortality in such patients. 
 In patients  with chronic liver disease platelet dysfunction is an important 
contributing factor for bleeding which is not usually recognized in the routine 
clinical practice. Moreover tests assessing the functional status of platelets are 
seldom done  in the laboratory due to various reasons.
This  study  is  conducted  from  a  tertiary  referral  centre  for 
gastroenterological problems offering services free of cost to poor sections of 
the  society.Patients  who  presented  to  our  hospital   with  various  complaints 
pertaining to chronic liver disease as well as those who were referred as chronic 
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liver disease were taken  up for the study. Their blood samples were taken for 
analysis of platelet dysfunction and the tests were carried out in the Department 
of Biochemistry, Bharathi Women’s College (Autonomous), Chennai.
2
AIM OF THE STUDY
3
To assess the  qualitative platelet function in patients with chronic liver 
disease.
1. To analyse   the   severity of   platelet dysfunction in chronic liver 
disease patients   with UGI bleed.
2. To compare the individual qualitative platelet function test in chronic 
liver disease patients.
3.  To  assess  the  contribution  of  platelet  dysfunction  in  UGI  bleed 
occurring   in   lesser grade of esophageal varices with relatively good 
liver function.
4. To  determine  the  significance  of  regular  assessment  of  qualitative 
platelet function in patients with chronic liver disease. 
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LITERATURE REVIEW
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Introduction
Chronic Liver Disease
Chronic liver disease is an entity which can be due to different causes 
and resulting in altered hepatic function and eventually portal hypertension. 
Cirrhosis  is  the end stage of  chronic  liver  disease  and is  characterized  by 
fibrosis and conversion of normal liver architecture into structurally abnormal 
nodules. 
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In the western world, the most common cause of cirrhosis is infection 
with  hepatitis  C followed by  alcohol  abuse.  But  in  our  country,  the  most 
common cause of cirrhosis is alcohol abuse followed by hepatitis B. Other 
causes of cirrhosis are non-alcoholic steatohepatitis, autoimmune, metabolic, 
biliary  and  genetic  disorders.  The  relative  proportion  of  patients  with 
“cryptogenic cirrhosis” is decreasing progressively.
Clinically  cirrhosis  can  be  divided  into  compensated  and 
decompensated  stages,  each  with  different  diagnostic,  therapeutic  and 
prognostic implications.
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Compensated  cirrhosis  may  be  totally  asymptomatic  and  diagnosed 
during routine biochemical testing or clinical or ultrasonographic abdominal 
examination. It  may also become evident during abdominal surgery and or 
autopsy. Nonspecific asthenia, malaise, upper quadrant abdominal discomfort, 
or sleep disturbance may be the only complaint.  On physical  examination, 
spider  angioma may be found,  mostly  on the trunk,  face and upper limbs. 
Their  number  and  size  co-relate  with  disease  severity.  Palmar  erythema 
involving the thenar and hypothenar eminences is the expression of a dense 
network of arterio-venous anastamosis.White nails may also appear. Common 
in male  patient is hair loss on the chest and abdomen. Gynaecomastia and 
loss of libido may also occur. Petechaie and ecchymosis may be present as a 
result of thrombocytopenia and or prolonged prothrombin time. Duputyren’s 
contracture involving the palmar fascia is particulary common in alcoholic 
patients. Hepatomegaly is very common, but liver size may also be normal or 
reduced.  However,  the  consistency  of  the  liver  is  invariably  harder  than 
normal.  Splenomegaly  is  frequent  and  indicates  presence  of  portal 
hypertension. Collateral circulation on the abdominal wall may develop as a 
consequence of portal hypertension.
In decompensated cirrhosis, signs of decompensation -ascites, variceal 
hemorrhage,  jaundice  and  porto-systemic  encephalopathy  are  found  at 
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presentation in a proportion of patients, varying between 20 and 63%. Ascites 
by  far  most  frequent  sign  of  decompensation,  being  present  in  80%  of 
patients.  On  examination,  patients  with  advanced  cirrhosis  may  have 
malnutrition and muscle wasting, particularly in alcoholic cirrhosis. Jaundice 
and  or  ascites  may  appear.  Other  signs  of  decompensation  are  those  of 
encephalopathy, as flapping tremor, bradylalia and mental  state alterations. 
Frequently associated with encephalopathy and severe liver dysfunction is a 
sweetish smell of breath, fetor hepaticus. Hypotension and tachycardia due to 
hyperdynamic circulation secondary to portal hypertension may be present. 
Dyspnoea may also occur due to presence of large ascites, pleural effusion 
and or alteration of pulmonary circulation. 
Diagnostic methods.
Liver biopsy still remains the gold standard for assessing the liver 
fibrosis  and  cirrhosis  despite  the  limitation  of  sampling  error  and  inter 
observer variability. However, eventhough definite tests such as histological 
diagnosis  are  important  for  patients  and  for  the  quantitative  evaluation  of 
treatment outcomes in clinical studies, non-invasive tests to estimate disease 
probability are necessary.
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The presence of firm liver has been shown to be the most accurate sign 
of cirrhosis, with a diagnostic accuracy of 83% followed by the presence of 
collateral circulation(accuracy 77%).
A  value  ≥1  for  the  ratio  of  aspartate  aminotransferase  to  alanine 
aminotransferase (ALT/AST or AAR) has been proposed as a simple low cost 
predictor of cirrhosis in viral cirrhosis. A reduced platelet count ( ≤ 150 to ≤ 
130 x 10 9 / L) indicate the presence of cirrhosis. Prolonged prothrombin time 
also  correlated  with  presence  of  cirrhosis.  Recently,  serum  hyaluronate 
measurement  has  been  shown  to  have  an  accuracy  of  about  90%,  being 
particularly useful for excluding the presence of cirrhosis.
Ultrasonography  is  a  useful  tool  for  diagnosis  as  it  may  detect 
nodularity of liver surface, portal hypertension, splenomegaly and ascites.The 
sensitivity of ultrasonography in detecting portal hypertension has been shown 
to be 80% with a specificity of 100%, when assessing the lack of respiratory 
variation  of  splenic  and  superior  mesenteric  vein.  The  detection  of  liver 
nodular surface and detection of mean portal velocity shows 79% sensitivity 
and 80% specificity.
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Upper digestive endoscopy has a definite role in the diagnostic workup 
as  it  may  identify  the  presence  of  esophageal   and  /or  gastric  varices  or 
congestive gastropathy. In compensated patients, the presence of esophageal 
varices has a sensitivity of 40% and a specificity of 99%.
In conclusion, a combination of clinical, biochemical, ultrasonographic 
and  endoscopic  data  can  establish  the  diagnosis  of  cirrhosis  without  liver 
biopsy with an accuracy of about 90 %.However when a precise determination 
of stage of fibrosis and degree of inflammation is required , liver biopsy  is 
necessary.
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 CLINICAL STAGING
No Varices
No ascites
Varices
No ascites
Ascites ±
Varices
Bleeding ±
Ascites
Stage  0
Stage  1
Stage 2
Stage 3
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Treatment and Prevention
The treatment of compensated cirrhosis is essentially based on careful 
avoidance of alcohol and hepatotoxic drugs and early detection of initial signs 
of decompensation.An adequate nutrition regimen should include 1-1.5 gm 
protein/kg body weight .
Treatment  of  cirrhosis,particularly  in  the  compensated  phase  of  the 
disease , should be aimed at the interruption of fibrogenesis and the resorption 
of fibrosis.However, so far no drugs have been approved as antifibrotic agents 
in humans and the most effective way to eliminate or reduce hepatic fibrosis is 
to treat the underlying liver disease.A reduction in fibrosis has been reported 
in  some  patients  with  chronic  infection  with  HCV treated  with  interferon 
alpha and ribavirin. Whether this effect may be reproduced also in cirrhotic 
patients  is  under  investigation.  No  treatment  has  yet  been  shown  to  be 
effective in preventing the development or progression of esophageal varices.
The management of decompensated cirrhosis consists of treatment of 
complications and the only curative treatment is liver transplantation.
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 Prognosis of chronic liver disease
The outcome of cirrhosis is determined by 3 major factors
1. Survival time within the compensated phase
2. The intensity of transition from compensated to decompensated state
3. Survival while in the decompensated state.
The  natural  history  of  compensated  cirrhosis  is  still  poorly  defined 
because patients are almost invariably free of symptoms and the diagnosis 
is  usually  prompted  by  casual  discovery  of  abnormal  liver  function. 
Patients  with  compensated  liver  cirrhosis  die  after  transition  into 
decompensated  cirrhosis.  The  10  year  survival  rate  for  compensated 
patients is nearly 90%, while the median survival after decompensation is 
about  2  years.  The  progression  to  decompensation  parallels  the 
development and progression of portal hypertrension. The 10 year survival 
rate of decompensation is 10 %.
In  patients  with  compensated  cirrhosis,  the  development  and 
enlargement of esophageal varices mark the progression of disease towards 
a  more  advanced  state.  When  cirrhosis  is  diagnosed,  the  prevalence  of 
varices  ranges  from  20%  in  compensated  patients  to  60  %  in  those 
presenting  with  ascites.  The  incidence  of  esophageal  varices  in  newly 
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diagnosed cirrhosis is nearly 5 % per year. 
Varices don’t develop below a threshold HVPG of 10-12 mm of Hg. 
Above  this  threshold,  the  median  time  to  development  of  varices  and  or 
bleeding  or  other  complications  of  portal  hypertension  is  about  4  years. 
Worsening liver function and continued exposure to alcohol are associated 
with an increase of HVPG with an  increasing risk of  developing varices.
Once varices have developed, they increase in size from small to large 
before they eventually rupture and bleed. Median progression probability from 
small  to large varices is  0.07 per  year.  Improvement in liver  function and 
abstinence from alcohol may result  in a decrease or even disappearance of 
varices, probably through a decrease in HVPG, as occurs for spontaneous or 
treatment induced HVPG reduction. Thus HVPG plays a key role in both the 
development and progression of varices.
Increasing  size  of  esophageal  varices  associated  with  increasing 
bleeding risk (4 fold from absent to small varices, and 2 fold from small to 
large varices). A similar in risk has been shown for the development of 
ascites and mortality.
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In clinical practice the size of the varices is the most widely used 
indicator  of  first  variceal  bleeding,  because  this  risk  is  significantly 
reduced by prophylactic therapy in patients with medium to large varices. 
All  patients  with  cirrhosis  should  be  endoscopically  screened  for  the 
presence  of  esophageal  varices  at  the  time  of  diagnosis  of  cirrhosis. 
Endoscopy should be repeated every 2-3 years in patients with cirrhosis 
without varices. In patients with compensated cirrhosis and small varices, 
endoscopy should be repeated every 1-2 years to detect the progression 
from small to large varices. In decompensated patients without varices or 
with small varices , endoscopy should be repeated yearly.
The median survival after first variceal haemorrhage is about one year 
(2 years if time zero is day 30 after the onset of bleeding) and after the 
development of ascites, it is 2 years.Encephalopathy and jaundice usually 
occur  after  bleeding  or  ascites  and  the  median  survival  after  the  first 
appearance  of  encephalopathy  or  after  the  appearance  of  jaundice  is 
therefore shorter than that for bleeding or ascites. The most frequent cause 
of death is bleeding, liver failure with hepatic coma, sepsis and hepatorenal 
syndrome. 
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Outcome of cirrhosis as related to clinical stage
No Varices
No ascites
Varices
No ascites
Ascites ±
Varices
Bleeding ±
Ascites
Death
7%
57%
20%
1%
3.4%
6.6%
7.6%
Stages in the progression of cirrhosis
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Prognostic Scores
Child’s Classification
A B C
S.Bilirubin <2 2 to 3 >3
S.Albumin >3.5 3 to 3.5 <3
Ascites None Easily controlled Poorly controlled
Neurological disorder None Minimal Advanced coma
Nutrition Excellent Good Poor wasting
Numerous tests and formulas have been proposed , no method to assess 
functional hepatic reserve is uniformly accepted. Of these , the child pugh 
score is the best established .
The score is based on simple clinical variables (Encephalopathy and ascites ) 
and blood test values ( Serum bilirubin and albumin levels and prothrombin 
time ) 
CP grading of severity of  liver disease was used to select   a suitable 
candidate  for shunt surgery who is likely to survive the operative 
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procedure .
Child pugh class a patients are operative candidates. If there is no ascites  or 
encephalopathy , the bilirubin level is less than 3mg /dl , the albumin level 
greater than 3g / dl  with an international normalized ratio less than or equal 
to 1.5 , the surgeon can operate on this patient with the expectation of a 
reasonable outcome . Child pugh class B patients may either class B 
improving towards to class A or class B moving towards class C.
In case of Child pugh class C patients, the only realistic operation is liver 
transplantation.
Numerous studies have failed to confirm its value in predicting morbidity 
and mortality after liver resection
Child Pugh Scoring System
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POINTS
1 2 3
Encephalopathy None 1 to 2 3 to 4
Ascites Absent Slight/controlled by 
diuretics
At least moderate
despite diuretics
Bilirubin <2 2-3 >3
Albumin >3.5 2.8-3.5 <2.8
Prothrombin
(seconds prolonged)
<4 4-6 >6
INR <1.7 1.7-2.3 >2.3
Cholestatic disease 
PBC/PSC
<4 4-10 >10
For  primary  biliary  cirrhosis  ,primary  sclerosing  cholangitis,  or  other 
cholestatic liver disease.
Grade A 5 - 6
Grade B 7 - 9
Grade C 10 - 15
Indices of liver dysfunction 
Formulae for estimating the short –term prognosis of patients with alcoholic 
liver disease:
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1. Composite clinical laboratory index (CCLI): Orrego and co-workers 
(1978) defined a group of parameters that correlate with mortality in 
hospitalized patients with alcoholic hepatitis. Calculation of the CCLI 
permits a linear estimate of acute mortality.
2. Maddrey’s  discriminant function (DF): Maddrey and co workers 
(1978) simplified the assessment of outcome of alcoholic liver disease 
by developing a discriminant function.
DF= 4.6 * (the difference between the patient’s and control prothrombin 
time )+ serum bilirubin.
Patients with a DF greater than 32 have a 50% chance of dying during 
current hospitalization. This index offers the advantage of few variables 
and easy computation (and therefore easy to recall) but is relatively 
imprecise. Fifty percent of patients with a DF grater than 32 will survive 
the hospitalization.
The clinical tool is used most widely to determine prognosis in patients with 
alcoholic cirrhosis is the child turcotte pugh (CTP) classification. This 
simple classification system, which was designed specifically to assess the 
risk of requirement for portacaval shunt surgery in cirrhotic patients with 
variceal bleeding, has gained favor as a rapid method for determining the 
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prognosis of patients with various chronic liver diseases. The CTP 
classification is as effective as quantitative liver function tests and disease – 
specific prognostic models for determining short term prognosis in groups of 
patients awaiting liver transplantation . Despite its limitations , the CTP 
classification has been adopted widely for risk-stratifying patients with 
cirrhosis because of its simplicity and ease of use. Five year survival rates 
for patients with alcoholic cirrhosis decrease dramatically as the CTP class 
becomes higher at the time of clinical presentation.
The development of ascites, variceal bleeding, hepatic 
encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome 
also has a significant impact on the prognosis of patients with alcoholic 
cirrhosis. The 5 year survival rate for persons in whom any of these 
complications develop is only 20% to 50% of that for patients with 
compensated cirrhosis.  The most ominous complications are spontaneous 
bacterial peritonitis and rapid onset hepatorenal syndrome. Less than one 
half of the patients in whom spontaneous bacterial peritonitis develop can be 
expected to survive 1 year; the median survival of patients with hepatorenal 
syndrome is less than 2 weeks.
22
Other models that have been used to predict prognosis in patients with 
alcoholic cirrhosis are the proportional hazards model developed by poynard 
and colleagues, the beclere model  and the prognostic model for end –satge 
liver disease   (MELD) developed by investigators at the Mayo clinic. The 
beclere model which was developed from a database of 818 patients with 
alcoholic cirrhosis who were followed prospectively for 4 years, includes the 
serum bilirubin level , serum albumin level , patients age  and presence or 
absence of hepatic encephalopathy . The MELD model, which originally 
was developed to assess short term prognosis in patients undergoing 
transjugular intrahepatic portosystemic shunt placement, includes the serum 
creatinine level , INR  and serum bilirubin level. This model has been shown 
to be useful for predicting short term survival in groups of patients with 
various liver diseases.
Abstinence from continued excessive drinking is the most important 
predictor of survival in patients who survive an initial hospitalization for 
alcoholic cirrhosis. The rate of survival over the ensuing 2 years is 70% to 
80% among patients who abstain or dramatically reduce their excessive 
drinking, compared with only 20% to 30% in those who continue to drink 
heavily.
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                            Child turcotte-pugh score
Comparison studies concluded that three global indices of severity (CTP 
,CCLI  and maddrey index) all have  approximately the same value for 
predicting mortality with the exception maddrey index ,which  is slightly 
less reliable.
Child’s grade is used to assess hepato cellular function in cirrhosis . Every 
patient should be assigned a grade.
5 years 
survival 
rate%
A                    B                 C
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It is the most important predictor of the likelihood of bleeding (in chronic 
liver patients who are having oesophageal varices ). It correlates with 
variceal size and with the presence of endoscopic red   signs and with the 
response to treatment.
Child’s grading and hospital death at index bleed
Grade A 5%
Grade B 18%
Grade C 68%
Total 50%
PLATELETS
Platelets (thrombocytes) are anucleate cells seen in the blood which are 
derived from the megakaryocytes in the bone marrow. It is of 2-4 µm in size 
and is of irregular or oral disc in shape. Normal platelet count in an adult is 
2-4 lakh/cu mm.
Platelets  are  surrounded  by  a  plasma  membrane  with  a  thick 
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glycoprotein  coat,which  is  responsible  for  their  adhesive  properties.  The 
cytoplasm  of  platelets  contain  microtubules,  mitochondria,  glycogen, 
endoplasmic reticulum and 3 major types of membrane bound vesicle, ie,
alpha,  delta  and  lambda  granules.  Microtubules  lies  beneath  the  plasma 
membrane  and  associated  with  actin  filaments,  myosin  and  other  proteins 
related to cell contraction. Alpha granules are the largest granules (500 nm) 
and  contains  platelet  derived  growth  factor  (PDGF),  fibrinogen  and  other 
substances. 
Platelets remain in the blood circulation for about 10 days. The 
megakaryocytes, giant cells in the bone marrow, form platelets by pinching 
off bits of cytoplasm and extruding them into the circulation. Between 60 and 
75 % of the platelets that have been extruded from the bone marrow are in the 
circulating  blood,  and  the  remainder  are  mostly  in  the  spleen.  They  are 
removed mainly by the splenic macrophages. Splenectomy increases platelet 
count.
The plasma membrane of platelets contain receptors for collagen, 
ADP, vessel  wall  von Willebrand factor  and fibrinogen. Platelets normally 
circulate  in  an  unstimulated  disk  shaped  form.  During  hemostasis  or 
thrombosis,  they  become  activated  and  help  to  form hemostatic  plugs  or 
thrombi. 3 major steps are involved (1) adhesion to exposed collagen in blood 
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vessels,(2) release of the contents of their granules and (3) aggregation.
Platelets adhere to collagen via specific receptors on the platelet 
surface,  including the glycoprotein complex GPIa-IIa  (α2β1 integrin),  in  a 
reaction that involves von Willebrand factor. This is a glycoprotein, secreted 
by endothelial cells into the plasma, which stabilizes factor VIII and binds to 
collagen and subendothelium. Platelets bind to von Willebrand factor via a 
glycoprotein complex (GPIb-V-IX) on the platelet surface; this interaction is 
especially  important  in  platelet  adherence  to  the  subendothelium  under 
conditions  of  high  shear  stress  that  occur  in  small  vessels  and  stenosed 
arteries.
Platelets adherent to collagen change shape and spread out 
on the subendothelium. They release the contents of their storage granules; 
secretion is also stimulated by thrombin.
Thrombin,  formed  from  the  coagulation  cascade,  is  the 
most potent activator of platelets and initiates platelet activation by interacting 
with  its  receptor  on  the  plasma  membrane.  The  further  events  leading  to 
platelet activation are examples of transmembrane signaling.The interaction of 
thrombin  with  its  receptor  stimulates  the  activity  of  an  intracellular 
phospholipase  Cβ.  This  enzyme  hydrolyses  the  membrane  phospholipids 
phosphotidyl 4, 5 biphosphate (PIP2) to form 1, 2 diacylglycerol and 1,4,5 
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inositol triphosphate.
Diacylglycerol  stimulates  protein  kinase  C,  which 
phosphorylates the protein pleckstrin. This results in aggregation and release 
of the contents of the storage granules. ADP released from dense granules can 
activate platelets, resulting in aggregation of additional platelets. IP3 causes 
release of Ca2 into the cytosol mainly from  the dense  granular system (or 
residual smooth endoplasmic reticulum from the megakaryocyte ), which then 
interacts   with  calmodulin  and  myosin  light  chain  kinase,  leading  to 
phosphorylation of the light chains of myosin. These chains then interact with 
actin, causing changes of platelet shape.
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Collagen-induced activation of a platelet phospholipase A2 
by increased levels of cytosolic Ca2+ results in liberation of arachidonic acid 
from platelet  phospholipids,  leading  to  the  formation  of  thromboxane  A2, 
which  in  turn,  in  a  receptor-mediated  fashion,  can  further  activate 
phospholipases C, promoting platelet aggregation.
Activated  platelets,  besides  forming  a  platelet  aggregate,  are 
required,  via  newly  expressed  anionic  phospholipids  on  the  membrane 
surface, for acceleration of the activation of factors X and II in the coagulation 
cascade.
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All  of  the  aggregating  agents,  including  thrombin,  collagen, 
ADP, and others such as platelet-activating factor, modify the platelet surface 
so  that  fibrinogen can  bind  to  a  glycoprotein  complex,  GPIIb-IIIa,  on  the 
activated platelet surface. Molecules of divalent fibrinogen then link adjacent 
activated platelets to each other, forming a platelet aggregate. 
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Clinical manifestations of disorders of primary Hemostasis.
(platelet defect)
Manifestations Defects of primary Hemostasis 
(Platelet Defect)
Onset of bleeding after trauma
Sites of bleeding
Physical findings 
Family history
Response for therapy
Immediate
Superficial – skin , mucous 
membranes,nose ,gastrointestinal and 
genitourinary tracts.
Petechiae , ecchymoses
Autosomal  dominant
Immediate: local measures effective
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Evaluation of Platelet Function
Platelet function in chronic liver disease
Platelet  abnormalities  found  in  patients  with  liver  disease  include 
reduced platelet count and functional disorders such as impaired aggregation 
and adhesion.
Thrombocytopenia in liver disease often is caused by sequestration in 
enlarged spleen.Shortened survival of platelets and fibrinogen in liver disease 
has  been  found.  Although  fibrinogen  survival  improved  after  the 
administration of heparin ,such an effect was not found on platelet , indicating 
that this would be dependent on mechanisms other than thrombin mediated 
platelet consumption.
In addition to the sequestration of platelets in the spleen, an impaired 
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synthesis of thrombopoietin may contribute to the thrombocytopenia seen in 
patients with liver disease.
In patients with alcohol related liver disease, there may be a direct toxic 
effect  of  ethanol  on  megakaryocyte  proliferation,  contributing  to 
thrombocytopenia.
Platelet  dysfunction  including  impaired  platelet  aggregation  of 
adenosine diphosphate,  epinephrine,  thrombin,  ristocetin in citrated platelet 
rich  plasma  has  been  described  in  patients  with  chronic  liver  disease.  In 
patients with a bleeding time more prolonged than expected from the platelet 
count,  an  abnormal  platelet  aggregation  appeared  to  correlate  with 
prolongation  of  bleeding  time.  The  functional  abnormalities  have  been 
attributed  to  an  inhibitory  effect  of  elevated  plasma  FDP  s  on  platelet 
aggregation or the presence of abnormal high density lipoproteins.  Moreover 
data have been reported indicating that platelet functional defect is intrinsic 
and not inducible by short term incubation of normal platelets in plasma from 
cirrhotic  patients.  Disturbances  of  prostaglandin  metabolism,  increased 
cholesterol  content  of  the  platelet  plasma  membrane  or  an  impairment  of 
platelet  transmembrane  signaling  mechanism  may  also  contribute  to  the 
defect.  
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Role of nitric oxide in the pathogenesis of primary hemostatic disorders 
associated with chronic liver disease.
Nitric  oxide  is  a  powerful  endothelium  derived  vasodilator  that,  in 
addition  to  the  relaxation  effect  on  vascular  smooth  muscle,  is  a  potent 
inhibitor  of  platelet  function.  It  has  been  demonstrated  that  nitric  oxide 
synthesized  by  the  constitutive  nitric  oxide  synthase  in  both  platelets  and 
vascular endothelium, inhibits platelet aggregation and adhesion, exerting its 
action  through activation  of  the  soluble  guanylyl  cyclase  and  elevation  of 
cyclic  GMP.  Under  pathological  conditions,  platelet  function  may  also  be 
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modified as a result of the expression of the inducible nitric oxide synthase. 
Recent studies suggest that increased nitric oxide formation plays a role in the 
pathogenesis  of  the  hemodynamic  abnormalities  associated  with  portal 
hypertension.
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METHODS
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MATERIALS AND METHODS
The study was conducted between January 2005 and March 2007 in 
the Government Peripheral  Hospital,  Annanagar. It  prospectively enrolled 
consecutive  60  patients  with  chronic  liver  disease.  The  inclusion  and 
exclusion criteria were as follows.
Inclusion Criteria
1. Patients  detected  to  have  chronic  liver  disesase  by  investigations  like 
ultrasonography, biochemical tests and endoscopy.
2. Patients presenting   with history suggestive of chronic liver disease and 
confirmed by various investigations
.
Exclusion Criteria
1. Patients  with  recent  surgery,  cardiopulmonary  bypass,  advanced 
malignancy,  sepsis,  disseminated  intravascular  coagulation,  renal 
dysfunction.
2. Patients on anticoagulants, antiplatelet drugs.

3. Patients  with  disorders  of  blood  like  polycythemia  vera,  essential 
thrombocythemia, thrombocytopenia, von Willebrand’s disease
     Data was collected at the time of presentation to our hospital.
Detailed  examination  of  the  patients  was  carried  out  including  general 
physical examination for any evidence of icterus, anemia and stigmata of 
chronic  liver  disease.  Cardiovascular,  respiratory  and  neurological 
examination  was  carried  out  to  look  for  any  evidence  of  systemic 
involvement.  A  detailed  abdominal  examination  was  done  to  look  for 
ascites,  hepatomegaly,  splenomegaly  and also  abdominal  wall  collaterals. 
All  the  patients  were  investigated  with  hemogram,  ESR,  total  and 
differential leucocyte counts, platelet count, blood sugar, blood urea, serum 
creatinine,  liver  function  tests  which  include  S.bilirubin  (total  & 
direct),SGPT, SGOT, total proteins,  albumin.  All the patients underwent 
ultrasonography  and  UGI  endoscopy  After  confirmation  of  chronic  liver 
disease blood samples were taken for qualitative platelet analysis which was 
carried  in  the  Department  of  Biochemistry,  Bharathi  Women’s  College 
(Autonomous), Chennai. 
Platelet  function  studies  that  were  assessed  were  tests  for  platelet 
adhesion (ADP-induced adhesion & collagen-induced adhesion),  tests  for 
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platelet  aggregation  (ADP-induced  aggregation  and  collagen-induced 
aggregation) and tests for estimation of nitric oxide (NO) production. (In 
mM of total nitrite /mg of PRP protein). 
Isolation of platelets
The method of Aster and Jandl, 1964 was adopted for the isolation of 
platelets. Briefly, 10 ml of blood was collected with acid citrate dextrose (2.5 
g of trisodium citrate, 2 g of dextrose and 1.5 g of citric acid in 100 ml of 
distilled water) anticoagulant in the ratio 9:1. The blood was then centrifuged 
at  160 x g for  10 min to obtain platelet  rich plasma (PRP).The PRP thus 
obtained was subjected to centrifugation at 300 x g for 5 minutes to pellet out 
the platelets.  The remaining plasma devoid of platelets is  the platelet poor 
plasma (PPP) and this is used as the control. The pelleted platelets were then 
washed  repeatedly  with  washing  buffer  containing  0.113M  NaCl,4.3 
mMK2HPO4, 4.3 mM Na2HPO4, 24.4 mM NaH2PO4 and 5.5 mM glucose , 
pH  6.5  to  obtain  erythrocyte  free  platelet  suspension  and  the  purity  was 
confirmed by microscopic examination. The washed platelet pellet was then 
suspended in platelet storage buffer containing 0.109 M NaCl, mM K2HPO4, 
4.3 mM Na2HPO4, 16 mM NaH2PO4, 8.3mM NaH2PO4 and 5.5 mM glucose, 
pH 7.5 and stored at 4o C until further analysis.
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Assay of platelet adhesion
Platelet adhesion was assayed by the method of Bellavite et al., 
1994. The harvested platelets were gently suspended in buffer containing 145 
mM NaCl, 5 mM KCl, 10 mM HEPES ,0.5 mM Na2HPO4, 6 mM glucose , 
0.2% human serum albumin in 1 litre distilled water with pH 7.4.Microplate 
coating was performed overnight  at  40 C by adding 100µl  /well  of human 
plasma diluted 1:1 at PBS or 20µl/ml collagen in 0.9% NaCl. Immediately 
before use, the plates were washed 2 times with 0.9% NaCl to avoid non-
specific binding of platelets. Immediately after coating and washing, the wells 
were  supplemented  with  25µl/of  agonist  4µM ADP/2µM collagen  /  fresh 
plant  extract.  The  plate  was  then brought  to  37oC and 50µl/of  prewarmed 
platelet (2.5x105 platelets) at 37o C was added to each well. The plate was 
incubated for 10 min at 37 C. At the end of incubation the wells were washed 
twice with 0.9% saline ( to remove non-adhered platelets) and were rapidly 
supplemented  with  150µl  of  0.1% Triton  X-100.After  incubation  at  room 
temperature for 1 hour the reaction was stopped and the colour was developed 
by the addition of 100µl of 2 N NaOH. The p-nitro phenol produced by the 
reaction was measured with Qualigens-SR 601 ELISA strip reader at 405 nm 
against a platelet free blank. The enzyme activity is the measure of platelet 
adhesion. The percentage of adherent cells was calculated on the basis of a 
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standard curve obtained with known number of  platelets.  The results  were 
expressed as % adhesion.
Platelet aggregation assay
Spectrophotometric method
Platelet aggregation was assayed by the method sited by  Bellavite et 
al.,(1994).The  method  is  based  on  the  measurement  of  turbidity  at  620 
nm.Briefly ,1.0 ml of the test agonist 4µM ADP/2µM collagen in buffer A 
(145  mM  NaCl,  5  mM  KCl,10  mM  HEPES  ,0.5  mM  Na2HPO4,  6  mM 
glucose  ,  0.2% human  serum albumin  in  1  litre  distilled  water,  pH  7.4.) 
supplemented with 3 mM CaCl2 and 3 mM MgSO4 was added with 1.0 ml of 
the  platelet  suspension  incubated  priorily  at  37o  C  and  the  increase  in 
transmission  at  620  nm  was  followed  over  time  with  Systronics  Visible 
Spectrophotometer-106.The percentage of aggregation was calculated on the 
basis of a standard curve obtained with known number of platelets.The results 
were expressed as %  aggregation.
ELISA method
Platelet aggregation was assayed by the method sited by Bellavite et al.,
(1994).The  method  is  based  on  the  measurement  of  turbidity  at  620  nm 
directly into microplates. Briefly ,the wells were supplemented with 100µl of 
the test agonist 4 µM ADP/2µM collagen in buffer A (145 mM NaCl, 5 mM 
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KCl,10 mM HEPES,0.5 mM Na2HPO4, 6 mM glucose , 0.2% human serum 
albumin in 1 litre distilled water, pH 7.4.) supplemented with 3 mM CaCl2 and 
3 mM MgSO4 .After the addition of 200 ul of the platelet suspension ,the strip 
was  incubated  at  37o C  and  the  decrease  in  absorbance  at  620  nm  was 
followed over time with Qualigens-SR 601 ELISAstrip reader.The percentage 
of aggregation  was calculated on the basis of a standard curve obtained with 
known number of platelets.The results were expressed as % aggregation.
Platelet secretion assay
0.5 ml of the agonist solution (4µM ADP) was added with 0.5 ml of test 
platelet suspension and for control; samples were added with distilled water 
devoid of agonist  and incubated at  37o C for 5 minutes.  The reaction was 
terminated  by  mixing  the  sample  with  0.5  ml  of  ice  cold  0.633  M 
formaldehyde in 0.05 M EDTA. The formaldehyde fixed aliquots were kept 
on ice for upto 60 minutes,. The aliquots were the n centrifuged at 12000 x g 
for  2 minutes at  room temperature.  The supernatants obtained contain,  the 
substances excreted from the platelets(Stest) and the substances in the water 
excreted  platelets(Scontrol).Additional  aliquots  for  the  determination  of  total 
contents (Tcontrol) of secretable substances. i.e., non-centrifuged samples were 
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also prepared simultaneously. The supernatants were treated with 0.3 ml of 
12N HCl and the fluorescent intensities of the samples were determined at an 
excitation wavelength of 303 nm and emission wavelength of 345 nm with 
ELICO-SL 174 Spectroflourimeter.  Percentage  secretion was calculated  by 
the formula:
Percentage secretion=[(S test-S control)/(T test-T control]x 100 
Where, S- amount of the substance in the supernatants
T-Total content
Estimation of nitric oxide
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Estimation of nitric oxide in  terms of total nitrite was based on the method of 
Griess (1879) modified by Fiddler (1977). This method is based on the Griess 
reaction in neutral solution which on exposure to the intermediates in the NO/
O2  reaction form an azo dye with NEDD and sulphanilamide. Nitrite forms 
significant amount of a nitrosating species only under acidic condition .The 
nitrate present in the sample cannot react with Griess reagent and so prior to 
45
the reaction nitrate is reduced to nitrite and then made to react with Griess 
reaction. The colour intensity of the azo dye measured at 520 nm is directly 
proportional to nitric oxide content in the biological sample
Reagents
1. Solution A :0.1% Naphthyl ethylene diamine dihydrochloride-100 mg 
of Naphthyl ethylene diamine dihydrochloride was dissolved in distilled 
water.
2. Solution B: 1% Sulphanilamide-1 g of Sulphanilamide was dissolved in 
100 ml 5 % phosphoric acid.
3. Griess reagent  -  Equal volumes solution A and solution B serves as 
griess reagent.
4.  5 % phosphoric acid—6.5 ml of 85% phosphoric acid was diluted  to 
100 ml with distilled water,
5. 35% Sulphosalicylic acid - 35 g of sulphosalicyclic acid was dissolved 
in 100 ml distilled water.
6. Reducing agent-Tin balls soaked in 6 N HCl.
7. Standard Sodium nitrite-0.005 mM/ml
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Procedure
0.7 ml of PRP was treated with 0.3 ml of sulphosalicylic acid and 
mixed well. Samples were vortexed for every 5 minutes for the total period 
of 30 minutes at room temperature and centrifuged at 3000 rpm for 30 
minutes.  0.5  ml  of  the  supernatant  was  mixed  with  1  ml  of  6  N HCl 
containing 3-4 tin balls. The contents were incubated at room temperature 
for 30 minutes with intermittent shaking in a dark environment. Then 1 ml 
of Griess reagent was added and allowed to stand for 20 minutes at room 
temperature protected from light. The color intensity developed was read at 
520 nm using Systronics 106-mono beam spectrophotometer. Aliquots of 
standard were also treated similarly.
The values were expressed as mM of total nitrite/mg of PRP protein.
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DISCUSSION
Platelet dysfunction is an important cause of bleeding in patients with 
chronic liver disease. Similar observations were obtained in
several other studies.
Our study group consists of 60 patients .Ther is a male predominance in the 
study (31 males versus 29 females)  
The whole study group(N=60) is characterized into two groups.
Group1  -  Those  who  presented  with  upper  gastrointestinal 
bleed(N=31)
Group 2-Those who presented without bleed (N=29)
The two groups contain almost equal number of patients.Our hospital 
being a tertiary referral centre; nine patients were referred as chronic liver 
disease. In 60 patients majority of the patients (ie, 50) had ascites of varying 
grades.24 patients were jaundiced.7 patients had sleep disturbances.None of 
the patients had frank encephalopathy.
The  most  common  etiology  of  chronic  liver  disease  patients  was 
alcohol abuse. 
All the patients’ undergone ultrasonography and all of them showed 
various features of chronic liver disease.
Those  patients  with  other  medical  illnesses  like  malignancy, 
thrombocytopenia etc were excluded.
The patients had undergone routine biochemical tests and in addition 
qualitative  platelet  function  studies.  The  function  studies  done  were  as 
Percentage   of  platelet  aggregation,  platelet  adhesion  and  estimation  of 
platelet nitric oxide. On comparing the platelet function studies it was found 
that  all  the  three  funtions  are  defective  in  chronic  liver  disease  patients. 
Among the functions,  estimation of nitric oxide appeared to be the most 
sensitive marker. There is a 35 % reduction in the % of platelet aggregation 
and 40% reduction in the % of platelet adhesion in patients with chronic 
liver disease compared to that of normal individuals. A study conducted in 
24 patients with portal cirrhosis and compared with platelet aggregation in 
14 normal subjects by Dr.Ballard H.S showed similar finding.
 All  the  three  platelet  function  tests  were  abnormal  in  both  the 
bleeding and non-bleeding group of patients with chronic liver disease .This 
finding was observed in studies done by Dr.Calabrese S and Dr.Giansante C.
Out   of  the  31  patients  who  presented  with  upper  gastrointestinal 
bleeding,26 patients(83%) showed   esophageal  varices  of  varying grades 
ranging  from  2  to  4  on  endoscopy.In  the  remaining  5  patients(16%),2 
patients  showed  grade  1 varices and three patients  showed no varices .
Platelet function tests of the three patients who had no varices were 
compared with those who have Grade 2-4 varices. In patients who presented 
with  upper  gastrointestinal  bleed  and  absent  varisces  on  endoscopy,the 
platelet function tests show s abnormalities which is similar to that seen in 
patients with GI bleed and varices.  This implies that platelet  dysfunction 
place a definite role in UGI bleed in chronic liver disease patients who have 
no varices.
The  severity  of  chronic  liver  disease  using  Child’s-Pugh  scoring 
system was defined.15 patients belonged to Child’s A, 16 patients in Child’s 
B and 29 patients in Child’s C. The platelet function tests were compared 
among the patients belonging to the above three groups. No correlation was 
found  between  the  severity  of  the  chronic  liver  disease  and  platelet 
dysfunction.

CONCLUSION
 
Qualitative  function  of  platelets  is  defective  in  all  patients  with 
chronic liver disease
1. There is no correlation between platelet dysfunction and bleeding in 
patients with chronic liver disease.
2. Estimation of nitric oxide in plasma appears to be a more sensitive 
marker  of  platelet  dysfunction  among the  various  tests  for  platelet 
dysfunction.
3. Platelet dysfunction is a contributing factor in UGI bleed occurring 
in  lesser  grade  of  esophageal  varices  with  relatively  good  liver 
function.
4. At  present  there  is  no  definite  role  for  assessment  of  qualitative 
platelet function in the routine management of patients with chronic 
liver disease. 
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                                     Proforma
1. Name:
2. DDHD Number:
3. Age:
4. Sex:
5. Symptoms:
Present History
(0=absent, 1=present)
6. Asymptomatic
7. Generalised weakness:
8. Right upper quadrant abdominal discomfort:
9. Yellow urine/yellow sclera/yellow discoloration of body:
10. Haemetemesis / melaena: 
11. Abdominal distension:
12. Swelling of legs:
13. Abdominal swelling:
General Examination (0=absent, 1=present)
 
14. Icterus:
15. Pallor:
16. Cyanosis:
17. Lymphadenopathy:
18. Evidence of malnutrition:
19. Palmar erythema
20. Duputryren’s contracture:
21. Spider naevi:
22. White nails:
23. Ankle edema
24. Flapping tremor
25. Cyanosis:
26. Hair loss:
27. Gynaecomastia:
Abdominal   Examination (0=absent, 1=present, 2=cannot be tested))
28. Hepatomegaly:
29. Splenomegaly:
30. Ascites:
31. Abdominal wall collaterals:
CNS Examination
32. Mental State Examination
33. Bradylalia
CVS Examination
Respiratory System Examination
Investigations (0=normal,1=abnormal,2=not done)
34. Hemoglobin:
35. Platelet count:
36. Liver function tests:
1. S.Bilirubin(Total &  Direct):
2. SGOT:
3. SGPT:
4. Total protein:
5. S.Albumin
36. Ultrasonogram
1. Liver size , echotexture and nodularity
2. Portal vein diameter and portal flow velocity
3. Respiratory variation of splenic and superior mesenteric vein
37. Endoscopy
1. Esophageal varices
2. Gastric varices
3. Congestive gastropathy
